Nectar Lifesciences LimitedQ1 FY27 Results & Financial Update
Nectar Lifesciences Limited: Q1 FY27 consolidated results and company financials – revenue ₹0.01 Cr, PAT ₹-15.40 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Nectar Lifesciences price & chart
Market price₹10.76
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Nectar Lifesciences Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Nectar Lifesciences reported continuing operations revenue of ₹0.0145 crore for the quarter ended June 30, 2026, alongside other operating income of ₹42.76 lakh, reflecting the substantially altered operational scale following prior-year business divestments.
Total income for Q1 FY27 reached ₹3.3620 crore, largely driven by other income of ₹3.3475 crore rather than core manufacturing operations.
The board of directors approved financial results for the quarter during its meeting on August 14, 2026, noting that the company continues to operate on a going concern basis backed by surplus liquidity from previous asset sales after discharging debt.
The company posted a loss before tax from continuing operations of ₹24.6195 crore for the quarter. Total tax expense stood at a negative ₹8.9008 crore, resulting in a net loss from continuing operations of ₹15.3977 crore.
01 · Business model
What does Nectar Lifesciences do?
Nectar Lifesciences Limited operates primarily in the pharmaceutical sector, focusing traditionally on active pharmaceutical ingredients (APIs), formulations, and related health products.
Following significant business restructuring, including the disposal of core operating assets through slump sales, the company's operational profile has undergone a transition towards non-core asset monetization and evaluating new business avenues.
The corporate office is located in Chandigarh, with manufacturing and operational footprints historically centered in Punjab and Himachal Pradesh.
02 · Historical context
What shaped the business before this quarter
During FY26, the company sold a substantial part of its existing business operations via slump sale, generating significant liquidity and allowing it to discharge all debts.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹0.01 Cr |
| Total income | ₹3.36 Cr |
| Profit before tax | ₹-24.62 Cr |
| Profit after tax | ₹-15.40 Cr |
| EPS | ₹-0.79 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Direct sales from continuing operations stood at just ₹1.45 lakh for the quarter, reflecting the absence of scaled commercial manufacturing following asset divestments.
Other operating income contributed ₹42.76 lakh during the quarter.
Revenue from operations for Q1 FY27 stood at ₹0.0145 crore, reflecting minimal active commercial billing under continuing operations during the quarter.
Other operating income contributed ₹4.2760 crore to the quarterly accounts, while general other income added ₹3.3475 crore.
What drove margins
Other expenses surged to ₹26.6366 crore, heavily influenced by a loss of ₹25.1329 crore recognized on surplus funds deployed in mutual funds, ETFs, and equity instruments due to market volatility.
Employee benefit expenses stood at ₹1.0637 crore, while finance costs were contained at ₹0.1569 crore for continuing operations.
Total expenses for the quarter amounted to ₹2.7981 crore on a consolidated basis, which included employee benefits expense of ₹1.0637 crore, finance costs of ₹0.1569 crore, depreciation and amortisation of ₹0.1106 crore, and other expenses of ₹26.6366 crore.
Surplus funds deployed in mutual funds, ETFs, and equity instruments experienced adverse valuation impacts due to market conditions and geopolitical developments, resulting in a recognized loss of ₹25.1329 lakhs under financial instruments.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates exclusively in the pharmaceutical business segment, although management has evaluated real estate and other non-core monetization paths.
The company operates exclusively in the pharmaceutical business segment for its continuing operations, while divested manufacturing units are accounted for under discontinued operations in compliance with Ind AS 105.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Fixed assets pertaining to the inoperative Jammu unit were disposed of in the subsequent quarter following the balance sheet date, and vacant land near Garhshankar, Punjab, has undergone partial monetization.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The company holds two wholly owned subsidiaries: Neclife PT, Unipessoal LDA (inoperative) and Avensis Exports Private Limited (AEPL), supporting strategic pivots.
Following the amendment of its object clause and the acquisition of Avensis Exports Private Limited as a wholly owned subsidiary, the company is actively evaluating potential projects within the real estate sector.
08 · Reported developments
What changed operationally
The company remains entirely debt-free following the complete discharge of obligations from previous asset monetization transactions.
09 · Pressure points & risks
What is not going smoothly
Adverse financial market conditions and geopolitical developments resulted in a loss of ₹25.1329 crore on surplus fund deployments in mutual funds and equities under Ind AS 109.
Fluctuations in financial markets and geopolitical events created adverse valuation pressure on surplus fund deployments, leading to a recognized market loss of ₹25.1329 lakhs.
10 · Items worth noticing
The line items that can distort a quick read
A charge of ₹25.1329 crore was recognized in the profit and loss statement due to volatility-induced losses in mutual funds, ETFs, and equity investments.
Recognized a loss of ₹25.1329 lakhs in the Statement of Profit and Loss under Ind AS 109 due to volatility impacting surplus funds invested in mutual funds, ETFs, and equities.
11 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Following the discharge of all debt obligations from prior business slump sales, the company retains adequate cash and liquid resources to meet its ongoing corporate obligations.
Capital allocation & funding
The company successfully discharged all its debt obligations during the preceding financial year from slump sale proceeds and is classified as 'Not a Large Corporate' under SEBI debt fundraising guidelines.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
Board reconstitution and director appointment
Dr. Gunmala Suri was appointed as an Additional Director in the capacity of Non-Executive Non-Independent Director effective August 15, 2026, and board committees including the Audit Committee were reconstituted.
Reported update
Discontinued asset monetization
The company progressed on monetizing non-core assets, including the capsule business slump sale to Capnest Health Care Private Limited for ₹1,990.00 lakhs and disposal of fixed assets at the Jammu unit.
Reported update
Annual General Meeting Schedule
The company scheduled its 31st Annual General Meeting for Friday, September 18, 2026, with share transfer books closed from September 12 to September 18, 2026.
13 · Key Q&A
The quarter, answered directly
What does Nectar Lifesciences do?
Nectar Lifesciences Limited operates primarily in the pharmaceutical sector, focusing traditionally on active pharmaceutical ingredients (APIs), formulations, and related health products.
What is the clearest takeaway from Q1 FY27?
Nectar Lifesciences reported continuing operations revenue of ₹0.0145 crore for the quarter ended June 30, 2026, alongside other operating income of ₹42.76 lakh, reflecting the substantially altered operational scale following prior-year business divestments.
What drove revenue or demand?
Direct sales from continuing operations stood at just ₹1.45 lakh for the quarter, reflecting the absence of scaled commercial manufacturing following asset divestments.
What mattered most for margins or profitability?
Other expenses surged to ₹26.6366 crore, heavily influenced by a loss of ₹25.1329 crore recognized on surplus funds deployed in mutual funds, ETFs, and equity instruments due to market volatility.
What changed operationally beyond the headline numbers?
Fixed assets pertaining to the inoperative Jammu unit were disposed of in the subsequent quarter following the balance sheet date, and vacant land near Garhshankar, Punjab, has undergone partial monetization.
What are the main pressure points disclosed for the quarter?
Adverse financial market conditions and geopolitical developments resulted in a loss of ₹25.1329 crore on surplus fund deployments in mutual funds and equities under Ind AS 109.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Capsule business transaction completion: Finalization and completion of the slump sale of the Empty Hard Gelatin Capsule business in Baddi, Himachal Pradesh, subject to statutory approvals.
- 02
Real estate project evaluation: Progress on evaluating and executing potential real estate projects under the revised business framework.
- 03
Land Monetization in Punjab: Track the execution of the remaining land sales near Garhshankar, Punjab, anticipated to be finalized by the end of the financial year.
- 04
Real Estate Strategy Execution: Observe any definitive project announcements or capital commitments arising from the company's evaluation of the real estate sector.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.